O Klepp
Overview
Explore the profile of O Klepp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
648
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brydoy M, Fossa S, Klepp O, Bremnes R, Wist E, Bjoro T, et al.
Br J Cancer
. 2012 Nov;
107(11):1833-9.
PMID: 23169336
Background: The objective of this study was to assess markers of spermatogenesis in long-term survivors of testicular cancer (TC) according to treatment, and to explore correlations between the markers and...
2.
Kristiansen W, Andreassen K, Karlsson R, Aschim E, Bremnes R, Dahl O, et al.
Hum Reprod
. 2012 Mar;
27(5):1525-35.
PMID: 22402210
Background: Testicular germ cell tumour (TGCT) is the most common cancer in young men, and an imbalance between the estrogen and androgen levels in utero is hypothesized to influence TGCT...
3.
Wanderas E, Fossa S, Tretli S, Klepp O
Int J Oncol
. 2011 May;
4(3):681-8.
PMID: 21566977
In order to assess overall treatment-induced long-term morbidity after high-dose adriamycin-based chemotherapy +/- radiotherapy, clinically significant toxicity was studied in survivors after treatment of advanced germ-cell cancer who had received...
4.
Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes R, et al.
Ann Oncol
. 2010 Feb;
21(9):1858-1863.
PMID: 20142410
Background: To offer minimized risk-adapted adjuvant treatment on a community and nationwide basis for patients with clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT). The aim was to reduce...
5.
Haugnes H, Aass N, Fossa S, Dahl O, Klepp O, Wist E, et al.
J Cancer Surviv
. 2008 Sep;
2(3):128-37.
PMID: 18792787
Introduction: We examined if testicular cancer (TC) treatment is associated with any risk for cardiovascular morbidity or predicted mortality according to the SCORE model, in which a 10-year future risk...
6.
Haugnes H, Aass N, Fossa S, Dahl O, Klepp O, Wist E, et al.
Ann Oncol
. 2006 Oct;
18(2):241-8.
PMID: 17060482
Background: A possible explanation of the excess cardiovascular risk in testicular cancer (TC) survivors is development of metabolic syndrome. The association between metabolic syndrome and TC treatment is examined in...
7.
Sagstuen H, Aass N, Fossa S, Dahl O, Klepp O, Wist E, et al.
J Clin Oncol
. 2005 Jul;
23(22):4980-90.
PMID: 16051950
Purpose: To evaluate blood pressure and body mass index (BMI) in long-term survivors of testicular cancer (TC) treated with different modalities. Patients And Methods: One thousand eight hundred fourteen patients...
8.
Schmoll H, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, et al.
Ann Oncol
. 2004 Aug;
15(9):1377-99.
PMID: 15319245
Germ cell tumour is the most frequent malignant tumour type in young men with a 100% rise in the incidence every 20 years. Despite this, the high sensitivity of germ...
9.
Risberg T, Kolstad A, Bremnes Y, Holte H, Wist E, Mella O, et al.
Eur J Cancer
. 2004 Feb;
40(4):529-35.
PMID: 14962719
This study reports on oncology professionals' knowledge and attitude toward complementary and alternative medicines (CAM), classified according to their primary application as complementary or alternative methods. In June 2002, we...
10.
Kolstad A, Risberg T, Bremnes Y, Wilsgaard T, Holte H, Klepp O, et al.
Support Care Cancer
. 2004 Feb;
12(5):312-8.
PMID: 14767750
Goals Of Work: It is well documented that an increasing proportion of cancer patients today use complementary and alternative medicine, mostly alongside conventional therapies. This study investigates the use of...